Last Update 24 Jul 26
Fair value Increased 70%ABSI: Hair Loss And Endometriosis Readouts Will Drive The Next Phase
Analysts have raised their blended Absci price target from about $10 to roughly $17, citing stronger views on the potential of lead asset ABS-201 after positive interim Phase 1 data, expanded modeled sales in endometriosis and androgenetic alopecia, and reduced near-term balance sheet risk following recent financing.
Analyst Commentary
Recent research coverage on Absci centers on how quickly ABS-201 has moved from a platform proof point to the key driver of valuation, with price targets and models now increasingly tied to the drug's potential in androgenetic alopecia and endometriosis.
Bullish analysts are highlighting two main themes: the readthrough from the positive interim Phase 1 data in the HEADLINE study, and the role of recent financing in reducing near term balance sheet risk. Both of these factors feed into higher price targets and more confidence in clinical execution.
Bullish Takeaways
- Several bullish analysts have lifted their Absci price targets into a US$9 to US$17 range, reflecting increased focus on ABS-201 as the primary valuation driver after the interim Phase 1 data.
- Models that now include ABS-201 in endometriosis, alongside androgenetic alopecia, point to a broader revenue opportunity, with one bullish analyst citing a risk adjusted peak sales estimate of US$549m for ABS-201 in endometriosis alone.
- Positive interim results from the blinded single ascending dose portion of the HEADLINE study, which included both healthy volunteers and participants with androgenetic alopecia, are seen as an early sign that clinical execution is tracking with expectations.
- The concurrent US$100m financing is viewed by bullish analysts as reducing near term balance sheet risk. Combined with the expanding ABS-201 program, this supports a more constructive stance on Absci's ability to fund its planned clinical work.
What’s in the News for Absci
- Absci completed a follow on equity offering of common stock totaling US$100.000003 million, issuing 13,495,277 shares at US$7.41 per share, with a discount of US$0.4446 per share. [Source: Follow on Equity Offerings filing]
- Interim Phase 1 data from the HEADLINE trial of ABS-201 reported that study medication appeared well tolerated across all blinded single ascending dose cohorts, with no serious adverse events and mainly mild treatment emergent adverse events such as headache. [Source: Product related press release]
- Interim pharmacokinetic data for ABS-201 indicated an estimated half life of at least 65 days, supporting the potential for two or three injections over a six month period, subject to further confirmation. [Source: Product related press release]
- The HEADLINE trial has progressed into the subcutaneous multiple ascending dose phase in participants with androgenetic alopecia. Absci indicated plans to report interim proof of concept data in the second half of 2026 and full proof of concept data in early 2027. [Source: Product related press release]
- Officers and directors of Absci are subject to lock up agreements on certain common stock and stock options, restricting sales and hedging transactions involving these securities for 60 days from the date of the prospectus. The lock up period is scheduled to end on 24 August 2026. [Source: End of Lock Up Period filings]
Valuation Changes for Absci
- Fair Value: The updated blended fair value estimate has increased from $10.00 to $17.00 per share, indicating a larger assessed upside in the Absci equity story relative to prior assumptions.
- Discount Rate: The modeled discount rate has moved slightly higher from 7.05% to 7.13%, implying a marginally higher required return for Absci in the refreshed analysis.
- Revenue Growth: The forecast revenue growth rate has been revised from 277.28% to 379.45%, pointing to a more expansive sales outlook for ABS-201 within Absci’s updated model.
- Net Profit Margin: The assumed net profit margin has increased from 16.03% to 27.19%, reflecting higher modeled profitability for the ABS-201 opportunity in Absci’s earnings profile.
- Future P/E: The forward P/E multiple has been reduced from 93.27x to 66.86x, indicating a lower valuation multiple being applied to Absci’s projected earnings despite the higher fair value estimate.
Catalysts
About Absci
Absci applies generative AI and biologics engineering to design and develop differentiated antibody therapeutics.
What are the underlying business or industry changes driving this perspective?
- Acceleration of ABS-201 into a Phase I/IIa trial for androgenetic alopecia, targeting interim proof-of-concept data in the second half of 2026, positions Absci to tap a large cash-pay aesthetic market and could drive step function growth in product revenue and operating leverage if efficacy is confirmed.
- Expansion of ABS-201 into endometriosis with a Phase II proof-of-concept trial planned for 2026, supported by strong mechanistic and competitor data, gives Absci exposure to a massive underserved women’s health market that can materially increase long term revenue visibility and earnings power.
- Best in class potential for ABS-201, including prolonged half-life, high concentration subcutaneous dosing and favorable preclinical pain and lesion data, supports a durable competitive moat that can translate into premium pricing, higher gross margins and improved long term net margins.
- Capital efficient development strategy that reuses ABS-201 safety data across both AGA and endometriosis, combined with the decision to partner ABS-101 and oncology assets, allows Absci to advance multiple multibillion dollar opportunities while limiting cash burn and supporting a faster path to positive operating income.
- Growing external validation of AI enabled drug discovery, together with Absci’s demonstrated ability to generate differentiated antibodies like ABS-301 and ABS-501, is driving increasing large pharma interest in platform partnerships that can add nondilutive collaboration revenue and milestone flows, improving earnings and extending the cash runway.
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more optimistic perspective on Absci compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
- The bullish analysts are assuming Absci's revenue will grow by 379.4% annually over the next 3 years.
- The bullish analysts assume that profit margins will increase from -6450.8% today to 27.2% in 3 years time.
- The bullish analysts expect earnings to reach $55.0 million (and earnings per share of $0.34) by about July 2029, up from -$118.4 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $-198.6 million.
- In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 67.1x on those 2029 earnings, up from -11.5x today. This future PE is greater than the current PE for the US Biotechs industry at 16.9x.
- The bullish analysts expect the number of shares outstanding to grow by 4.27% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.13%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- ABS-201 and ABS-101 are still in early clinical stages, so any underwhelming efficacy, safety signals or trial design issues in AGA or endometriosis could derail the company’s lead value drivers. This could limit the ability to scale product revenue and delay the path to positive earnings.
- The long timeline to key proof-of-concept readouts in the second half of 2026 for AGA and the second half of 2027 for endometriosis leaves a multi-year window in which sentiment could deteriorate if interim data are ambiguous or delayed. This could put sustained pressure on the share price and constrain future capital-raising options that underpin cash flow and earnings.
- Success of competitor prolactin receptor programs such as HMI-115 and continued reliance on legacy AGA treatments increase the risk that ABS-201 fails to achieve clear best-in-class differentiation in real-world use. This would limit pricing power, compress gross margins and reduce long-term net margins.
- The strategic pivot away from internal development of ABS-101, ABS-301 and ABS-501 increases dependence on finding strong pharma partners on attractive terms. Any slippage or weaker-than-expected deals would reduce anticipated nondilutive collaboration revenue and milestone inflows, shortening the cash runway and pressuring earnings.
- Absci’s model depends on large, multibillion-dollar markets that are partially cash pay and discretionary in nature, such as aesthetic hair regrowth, and on the continued willingness of pharma to fund AI-based drug creation. Any macro slowdown, reimbursement pushback or waning enthusiasm for AI drug discovery would dampen demand for its therapies and partnerships, limiting revenue growth, operating leverage and eventual net margins.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bullish price target for Absci is $17.0, which represents up to two standard deviations above the consensus price target of $13.78. This valuation is based on what can be assumed as the expectations of Absci's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $17.0, and the most bearish reporting a price target of just $10.0.
- In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $202.3 million, earnings will come to $55.0 million, and it would be trading on a PE ratio of 67.1x, assuming you use a discount rate of 7.1%.
- Given the current share price of $8.07, the analyst price target of $17.0 is 52.5% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Absci?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
